Table 1.
Patients characteristics.
Figure 1.
Distribution of EP class and EP clin class.
Distribution of EP class and EP clin class of all included EndoPredict assays (A). Distribution of EP class and EP clin class of a subgroup of patient for which therapy decision data were available (B).
Figure 2.
Test performance of the EndoPredict assay during one year.
167 samples could successfully analysed during one year.
Figure 3.
Distribution of the molecular risk score EP related to the histological grade and mitotic index.
Distribution of the molecular risk score EP related to the histological grade (A) as well as to the mitotic index (B). The continuous line revealed the median, the dotted line highlighted the cutoff point of the molecular risk score EP. The cutoff point of ki67 was extracted from the St. Gallen guidelines [2].
Figure 4.
Changes in therapy decisions regarding the decision before and after the EndoPredict assay.
Figure 5.
Therapy decision related to the molecular risk score EP and the combined clinical and molecular score (EPclin).
Association between the molecular risk score EP, the combined clinical and molecular score (EPclin) and therapy decision (A). The group of patient’s desire for other therapy was excluded. The dotted vertical line marks the cutoff values of the molecular risk score EP, the broken horizontal line marks the cutoff value of the combined clinical and molecular score (EPclin). Additionally, the therapy decisions related to the combined clinical and molecular score (EPclin) are shown (B). The broken horizontal line marks the cutoff value of the combined clinical and molecular score (EPclin), the continuous line indicates the median.